UBS Group set a $88.00 price target on Esperion Therapeutics (NASDAQ:ESPR) in a research report released on Wednesday, 99wallstreet.com reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently issued reports on the company. Stifel Nicolaus set a $105.00 price objective on Esperion Therapeutics and gave the company a buy rating in a research note on Monday, January 15th. BidaskClub upgraded Esperion Therapeutics from a buy rating to a strong-buy rating in a research note on Saturday, January 13th. Bank of America upgraded Esperion Therapeutics from a neutral rating to a buy rating and set a $76.00 price objective for the company in a research note on Friday, January 5th. Needham & Company LLC upgraded Esperion Therapeutics from a buy rating to a strong-buy rating and boosted their price objective for the company from $72.00 to $81.00 in a research note on Thursday, December 14th. Finally, Chardan Capital boosted their price objective on Esperion Therapeutics from $20.00 to $75.00 and gave the company a neutral rating in a research note on Wednesday, December 6th. Five research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $72.85.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up $2.24 during trading hours on Wednesday, hitting $77.20. The company had a trading volume of 501,580 shares, compared to its average volume of 460,565. The company has a market cap of $2,022.49, a P/E ratio of -11.24 and a beta of 2.73. Esperion Therapeutics has a 52 week low of $10.71 and a 52 week high of $78.59.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the prior year, the company posted ($0.77) earnings per share. sell-side analysts expect that Esperion Therapeutics will post -7.3 EPS for the current fiscal year.
In related news, Director Nicole Vitullo sold 9,326 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the transaction, the director now directly owns 2,472 shares of the company’s stock, valued at approximately $133,117.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 32.50% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Chartwell Investment Partners LLC purchased a new position in Esperion Therapeutics in the 3rd quarter worth approximately $1,374,000. Meditor Group Ltd lifted its holdings in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares in the last quarter. Macquarie Group Ltd. purchased a new position in Esperion Therapeutics in the 2nd quarter worth approximately $1,182,000. OxFORD Asset Management LLP purchased a new position in Esperion Therapeutics in the 3rd quarter worth approximately $715,000. Finally, Rothschild Asset Management Inc. purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $1,124,000. 92.35% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.truebluetribune.com/2018/01/21/esperion-therapeutics-espr-pt-set-at-88-00-by-ubs-group.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.